AstraZeneca's diabetes drug Xigduo approved in Europe
LONDON (Reuters) - AstraZeneca said European regulators had approved Xigduo for type 2 diabetes, in what was the first green light for a fixed dose combination of a SGLT2 inhibitor and metformin.
The drug combines in a twice daily tablet Forxiga, a SGLT2 inhibitor that reduces the reabsorption of excess glucose, and metformin, a standard in treating the condition.
Xigduo was developed by the alliance in diabetes therapy between the British company and Bristol-Myers Squibb, the companies said on Wednesday. AstraZeneca will take full control of the unit later this quarter.
- Children's corpses reveal desperate attempts to escape Korean ferry |
- Ukraine's leaders say have U.S. backing to take on 'aggressors'
- 'Bridgegate' scandal threatens next World Trade Center tower
- Obama seeks to ease Asian allies' doubts during visit to Japan |
- UPDATE 4-Children's corpses reveal desperate attempts to escape Korean ferry